Edith Cowan University

Research Online
ECU Publications Post 2013
1-1-2014

Pulmonary function in patients with Huntington's Disease
Alvaro Reyes
Edith Cowan University

Travis Cruickshank
Edith Cowan University

Mel Ziman
Edith Cowan University

Ken Nosaka
Edith Cowan University

Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013
Part of the Neurology Commons
10.1186/1471-2466-14-89
Reyes, A., Cruickshank, T., Ziman, M., & Nosaka, K. (2014). Pulmonary function in patients with Huntington’s
Disease. Bmc Pulmonary Medicine, 14(1), 89. doi:10.1186/1471-2466-14-89. Available here
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworkspost2013/203

Reyes et al. BMC Pulmonary Medicine 2014, 14:89
http://www.biomedcentral.com/1471-2466/14/89

RESEARCH ARTICLE

Open Access

Pulmonary function in patients with Huntington’s
Disease
Alvaro Reyes1*, Travis Cruickshank1, Mel Ziman1,2 and Kazunori Nosaka3

Abstract
Background: Huntington’s disease (HD) is a neurodegenerative disorder characterized by progressive motor,
cognitive and psychiatric disturbances. Chest muscle rigidity, respiratory muscle weakness, difficulty in clearing
airway secretions and swallowing abnormalities have been described in patients with neurodegenerative disorders
including HD. However limited information is available regarding respiratory function in HD patients. The purpose
of this study was to investigate pulmonary function of patients with HD in comparison to healthy volunteers, and
its association with motor severity.
Methods: Pulmonary function measures were taken from 18 (11 male, 7 female) manifest HD patients (53 ± 10 years),
and 18 (10 male, 8 female) healthy volunteers (52 ± 11 years) with similar anthropometric and life-style characteristics to
the recruited HD patients. Motor severity was quantified by the Unified Huntington’s Disease Rating Scale-Total Motor
Score (UHDRS-TMS). Maximum respiratory pressure was measured on 3 separate days with a week interval to assess
test-retest reliability.
Results: The test-retest reliability of maximum inspiratory and expiratory pressure measurements was acceptable for both
HD patient and control groups (ICC ≥0.92), but the values over 3 days were more variable in the HD group (CV < 11.1%)
than in the control group (CV < 7.6%). The HD group showed lower respiratory pressure, forced vital capacity, peak
expiratory flow and maximum voluntary ventilation than the control group (p < 0.05). Forced vital capacity, maximum
voluntary ventilation and maximum respiratory pressures were negatively (r = −0.57; −0.71) correlated with the
UHDRS-TMS (p < 0.05).
Conclusion: Pulmonary function is decreased in manifest HD patients, and the magnitude of the decrease is associated
with motor severity.
Keywords: Pulmonary function, Huntington’s disease

Background
Huntington’s disease (HD) is a degenerative disorder of the
nervous system characterized by progressive motor, cognitive and psychiatric disturbances [1,2]. Motor abnormalities
are caused by specific loss of medium spiny striatal neurons
that are responsible for the control, initiation and execution
of muscle movements [3]. Respiratory problems such as
chest muscle rigidity, respiratory muscle weakness, difficulty in clearing airway secretions and swallowing abnormalities have been reported in patients suffering from
neurodegenerative disorders including HD [4,5], but little
information is available regarding pulmonary function in
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HD patients. To the best of authors’ knowledge, only one
study reported that pulmonary function was reduced at
mid and later stages of HD, however the study was published in an abstract form only [6].
Most of the patients with HD do not report respiratory
symptoms until later stages of the disease when the impaired
motor control of swallowing muscles and respiratory muscle
weakness increase the risk of pneumonia by aspiration, causing death in the majority of patients with HD [3,7-9]. Presumably pulmonary function disturbances remain unnoticed
because patients suffering from HD tend to adopt a sedentary life style, with limited physical activity in which impairment of pulmonary function would be evident [10].
The level of pulmonary function impairments in manifest HD patients has not been described in detail to date,
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and no previous studies have assessed the association
between pulmonary function and the severity of motor
abnormalities in HD patients. It was hypothesized that
pulmonary function would be lower in manifest HD patients in comparison to age-matched healthy volunteers,
and the magnitude of the pulmonary deficiency would
be associated with an increased level of motor abnormalities of the patients. The present study compared pulmonary function in patients with HD with that of
healthy volunteers, and examined the association between pulmonary function and severity of motor abnormalities in manifest HD patients.

Methods
Participants

To determine the number of participants required for
this study, we performed a pilot study in which spirometry, maximum expiratory (MEP) and inspiratory pressures (MIP) were compared between manifest HD
patients and age-matched healthy volunteers. Given that
in HD, the main cause of death is an aspiration pneumonia event that is associated with an inability to clear airway secretions in which expiratory muscles have a major
role, [11] the sample size calculation was based on MEP.
It was estimated that there would be a difference of at
least 30 cmH2O (SD = 30) in MEP between HD patients
and healthy volunteers. With alpha 0.05 and 80% power,
an adequate sample size was calculated to be at least 13
participants per group.
Eighteen patients with manifest HD (11 men, 7 women)
were recruited using the Huntington’s Enrichment Research
Optimisation scheme database [12], with assistance from
the Huntington’s Western Australia Association. Inclusion
criteria were a positive genetic test, clinically verified
disease expression (Unified Huntington’s Disease Rating
Scale–Total Motor Score [UHDRS-TMS] ≥5), and the
ability to understand and respond to instructions.
Exclusion criteria were other confounding neurological
disorders, current smokers, occupational or ambient
exposure to pollutants that could have affected their
pulmonary function, patients with a history of cardiovascular pathology, lung disease, chronic obstructive
pulmonary disease (COPD) or the presence of respiratory symptoms such as cough, phlegm, wheezing or
dyspnoea at the time of assessment. Patients with HD
at later stages of the disease were not considered for
this study due to their incapacity to perform a satisfactory pulmonary function tests. The control group
(10 men, 8 women) consisted of mainly partners of the
recruited HD patients, and some people with similar lifestyle characteristics to the recruited HD patients.
Healthy volunteers were age and gender-matched with
the recruited HD patients. The same exclusion criteria as those for the HD patients were applied to the
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control group. Nine patients with HD and 6 healthy
volunteers had a previous history of smoking. Informed
written consent was obtained from participants and the
study was approved by the Human Research Ethics
Committee of Edith Cowan University. Characteristics
of the participants are presented in Table 1.
Maximum respiratory pressure measurement

For MIP and MEP measurements, each participant
was asked to sit upright with a nose clip in place to
prevent nasal air leakage. A flanged rubber mouthpiece
was connected to a pressure manometer (Micro RPM,
Micro Medical-Care Fusion, Kent, United Kingdom)
and placed in the mouth. Participants were asked to
hold the pressure manometer with both hands and to
create a tight lip seal around the flanged mouthpiece.
A flanged mouthpiece was used as recommended by
the American Thoracic Society/European Respiratory
Society (ATS/ERS), because it ensures the least air
leakage at the mouthpiece [13]. This method was
Table 1 Physical and physiological characteristics
(mean ± SD and ranges) of Huntington’s disease patients
(HD) and healthy volunteers (Control)
CAG repeat

HD

Control

p

43.7 ± 2.6

-

-

-

-

-

-

-

-

(40–48)
Disease Burden Score

421.6 ± 92.7
(284–615)

Illness duration (years)

5.4 ± 2.3
(3.3-10.2)

UHDRS-TMS

40 ± 15.7
(13 – 62)

Male/Female

11/7

10/8

-

Age (years)

53 ± 10

52 ± 11

0.359

(32 – 71)

(37 – 74)

Height (m)

1.70 ± 0.06

1.70 ± 0.09

(1.60 – 1.80)

(1.51 – 1.88)

74.5 ± 15.0

78.5 ± 14.5

(56 – 106)

(55 – 110)

26.0 ± 4.6

27.0 ± 3.9

(20.2 – 36.1)

(21.5 – 35.1)

19.1 ± 31.1

18.7 ± 6.1

(0.1 – 92.5)

(7.5 – 26.0)

24.4 ± 14.0

20.2 ± 10.1

(8 – 50)

(4 – 34)

Weight (kg)
BMI (kg/m2)

Smoking history of ex-smokers*
(pack-year)
Time elapsed from smoke cessation
of ex-smokers* (years)

0.479

0.209

0.177

0.487

0.267

P values were based on independent t-tests.
CAG: Cytosine-adenine-guanine, BMI: Body mass index. UHDRS-TMS: Unified
Huntington’s disease Rating Scale-Total Motor Score. Pack-year: average daily
number of cigarettes smoked divided by 20 and multiplied by the number of
years of smoking. *The number of ex-smokers was 9 for HD group, and 6 for
control group.
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used, since the portability of the manometer is advantageous for clinical use and its reliability has been
assessed [14].
For MEP assessment, participants were asked to breathe
in to total lung capacity and then to blow hard into the
mouthpiece. For MIP assessment, participants were
instructed to breath out to residual volume and then to
breath in with maximum effort through the mouthpiece.
Inspiratory and expiratory efforts were required to be
maintained for more than one second. The order of the
procedures were first the inspiratory followed by the
expiratory effort [13]. Both manoeuvres were repeated a
minimum of 5 times with a 30-s rest between measures to
minimize the effects of fatigue until three trials showed
values within 5% variation of each other. The best result
from the three respiratory manoeuvres was used for
further analysis as described by Black and Hyatt [15] and
the ATS/ERS guidelines [16]. Results of MIP and MEP
are expressed as absolute values, because no suitable
predictive equations are available.
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reported their cardio-vascular and smoking history as well
as their respiratory condition. The body mass and height
were recorded for each participant using an accurate and
calibrated scale (HW200, A&D Mercury Pty, Ltd, Thebarton, SA) and a wall-mounted stadiometer (Model 220,
SECA, Hamburg, Germany), followed by MIP and MEP
measurements performed over 3 testing sessions with a
week apart between sessions.
Thorough explanation, demonstration and practice were
provided before attempts at MIP, MEP and spirometric
measures. Each participant was instructed to perform spirometric maneuvers in the following order: SVC, FVC and
MVV. Each manoeuvre was repeated at least 3 and
maximum of 8 times, with 1–2 min rest between attempts.
The best result from the three technically acceptable
manoeuvres was used for further analysis. For those
participants who had difficulties achieving acceptable and
reproducible spirograms on the first testing day, the measurement was repeated on different days, to ensure an
accurate spirometry. The weekly measurements were taken
at the same place and time of day for each participant.

Spirometry

Spirometric assessment was performed using a spirometer (Medgraphics, model CPFS/D, St. Paul MN, USA)
connected to a laptop computer (Dell, Latitude E6510,
USA). The spirometer met all the quality control requirements of the ATS and was calibrated before each
testing session with a Hans Rudolph 3.0 syringe, based
on the manufacturer’s recommendations. In accordance
with the ATS/ERS guidelines [17], each participant was
asked to sit upright with a nose clip in place to prevent
nasal air leakage. Participants were instructed to perform
a slow vital capacity (SVC), a forced vital capacity (FVC)
and a maximal voluntary ventilation (MVV) manoeuvre.
From these measurements, forced expiratory volume in
one second (FEV1), peak expiratory flow (PEF) and the
ratio of FEV1 to FVC (FEV1/FVC) from the largest FEV1
and FVC were calculated. Predicted values were calculated for all participants using Stanojevic 2009 [18] prediction equations, which include age, height, weight and
gender. The equations include reference values for
FVC and FEV1, and have been validated for Caucasian
Australasian population [19]. Peak expiratory flow predicted values were calculated using Nunn and Gregg [20]
regression equations. Given that none of the participants
in the study had a confirmed diagnosis of COPD or presented with any known symptoms of COPD, such as
cough, sputum production or dyspnea at the time of the
assessment, a reversibility test with bronchodilator was
not performed.
Experimental procedures

All the participants of the study were interviewed and completed a general health questionnaire, in which they

Statistical analysis

Descriptive data are given as mean and standard deviation. Normality assumption for all continuous variables
was tested using the Shapiro-Wilk test. To assess the
test-retest reliability of MIP and MEP measurements for
each group (HD, control), the interclass correlation coefficient (ICC) and the coefficient of variation (CV) were
calculated. To compare spirometric variables, MIP and
MEP between HD patients and healthy volunteers, an independent t-test was performed. Relationships between each
pulmonary function measurement and UHDRS-TMS were
analyzed by a Pearson correlation coefficient. Statistical significance was set at p ≤ 0.05. All statistical analyses were
performed using STATA version 9.1.

Results
There were no significant differences between HD and
control groups for gender balance, age, height, body
mass and body mass index (Table 1). There were no significant differences in smoking history (p = 0.487) or in
the time elapsed since smoking cessation (p = 0.267) between groups (Table 1). A subgroup analysis in HD patients revealed no significant differences in pulmonary
function variables between non-smoker (n = 9) and exsmoker (n = 9) patients. A Shapiro-Wilk test showed that
the normality assumption was met for all variables including the variables in the subgroups.
Table 2 shows mean ± SD and range values of MIP
and MEP obtained at three different days for HD and
control groups. The test-retest reliability of MIP and
MEP measurements were acceptable in both groups with
no significant differences between three testing sessions.
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Table 2 Maximum inspiratory (MIP) and expiratory pressure (MEP) values (mean ± SD and [95% confidence interval]) of
Huntington’s disease patients (HD) and healthy volunteers (Control) for 3 different days (Day 1 – Day 3), Interclass
correlation coefficient (ICC) for the three measures on 3 different days, and coefficient of variation (CV) for Days 1–3,
Days 1 and 2, and Days 2 and 3
MIP

Day 1

Day 2

Day 3

ICC [95% CI]

CV (%) Day 1-2-3

CV (%) Day 1-2

CV (%) Day 2-3

64.2 ± 27.9

67.6 ± 32.4

68.6 ± 30.2

0.94

10.8

12.8

9.2

[50.3 – 78.1]

[51.5 – 83.7]

[53.6 – 83.6]

[0.89 – 0.98]

102.6 ± 27.7

106.8 ± 29.8

106.2 ± 28.5

0.95

5.6

6.0

5.2

[88.8 – 116.3]

[92.0 – 121.7]

[92.0 – 120.4]

[0.92 – 0.99]

94.7 ± 37.6

97.2 ± 36.8

98.5 ± 40.1

0.92

11.1

12.8

9.0

[76.0 – 113.4]

[78.3 – 118.8]

[78.9 – 115.5]

[0.86 – 0.98]

137.8 ± 33.4

142.2 ± 40.6

142.2 ± 40.8

0.92

7.6

7.9

4.8

[121.1 – 154.4]

[122.0 – 162.4]

121.8 – 162.5]

[0.86 – 0.98]

HD

Control

MEP

HD

Control

However, the variability for MIP values across testing
sessions was greater for HD (CV 10.8%) than control
group (CV 5.6%), and this was also the case for MEP
(HD: CV 11.1%, control: CV 7.6%). The variability in
MIP and MEP was lowest for the second and third testing days for both groups when compared with that for
the first and second days or across three days.
As shown in Table 3, the HD group showed significantly
lower maximum respiratory pressures, FVC, FEV1, PEF and
MVV compared with the control group for both absolute
and percentage of predicted values. The HD group also
showed lower inspiratory capacity (IC) and FEV1 than the
control group for percentage of predicted values. The
FEV1/FVC ratio was significantly greater in the HD group

compared to the control group. Five participants in the
control group and none in the HD group had a FEV1/FVC
ratio ≤0.7, these 5 participants in the control group had a
FEV1 (% predicted) greater than 0.7. One of the 5 participants with FEV1/FVC ≤0.7 was an ex-smoker. Eight participants in the HD group and 1 in the control presented a
FVC (% predicted) equal or lower than 70%. There was no
significant difference in SVC between groups.
Significant correlations between maximum respiratory
pressure and FVC or PEF were found only in the HD
group either for percentage of predicted values (Table 4)
or absolute values. Figure 1 shows relationships between
the UHDRS-TMS and pulmonary function variables
(percentage of predicted values). All of the variables

Table 3 Mean ± SD and 95% confidence interval (shown in [ ]) of each pulmonary function variable (absolute and/or
percentage predicted values: % predicted) for Huntington’s disease patients (HD) and healthy volunteers (Control)
HD

Control

p

MIP (cm H2O)

72.6 ± 30 [57.7 – 87.6]

110.1 ± 28.8 [95.8 – 124.4]

0.000

MEP (cm H2O)

106.2 ± 37 [87.8 – 124.5]

147.9 ± 38.4 [128.8 – 167.0]

0.001

2.7 ± 0.8 [2.3 – 3.1]

3.2 ± 0.8 [2.8 – 3.6]

0.063

97.0 ± 24.9 [84.7 – 109.4]

112.3 ± 14.2 [105.2 – 119.4]

0.015

3.8 ± 1 [3.3 – 4.4]

4.0 ± 1 [3.6 – 4.6]

0.237

92.2 ± 23.6 [80.4 – 103.9]

97.4 ± 11.4 [91.7 – 103.0]

0.203

3.1 ± 1.0 [2.6 – 3.6]

3.9 ± 1.0 [3.4 – 4.5]

0.008

72.8 ± 17.4 [64.2 – 81.5]

93.4 ± 13.4 [86.7 – 100.0]

0.000

2.6 ± 0.74 [2.2 – 3.0]

3.0 ± 0.72[2.7 – 3.3]

0.066

80.6 ± 16.8 [72.2 – 89.0]

92.4 ± 12.6 [86.1 – 98.6]

0.011

87 ± 7.4 [83.3 – 90.7]

77 ± 8.1 [73.3 – 81.4]

0.000

5.9 ± 2.0 [4.9 – 6.9]

7.3 ± 1.9 [6.3 – 8.2]

0.024

64.7 ± 18.4 [55.5 – 73.8]

81.1 ± 18.9 [71.7 – 90.5]

0.006

IC (L) % predicted

SVC (L) % predicted

FVC (L) % predicted

FEV1 (L/s) % predicted
FEV1/FVC
PEF (L/s) % predicted

MVV (L/min) % predicted

103.9 ± 43.0 [82.6 – 125.3]

142 ± 36.6 [124.7 – 161.1]

0.003

82.6 ± 27.3 [69.0 – 96.1]

117.1 ± 15.0 [109.5 – 124.5]

0.000

MIP: Maximum inspiratory pressure, MEP: Maximum expiratory pressure, IC: Inspiratory capacity, SVC: Slow vital capacity, FVC: Forced vital capacity, FEV1: Forced
expiratory volume in 1 second, PEF: Peak expiratory flow, MVV: Maximum voluntary ventilation.
p values as the results of the t-tests to compare between groups are included.
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Table 4 Correlation between maximum inspiratory pressures (MIP, absolute values) or maximum expiratory pressure
(MEP, absolute value) and pulmonary function variables (inspiratory capacity: IC, slow vital capacity: SVC, forced vital
capacity: FVC, forced expiratory volume in 1 second: FEV1, peak expiratory flow: PEF, maximum voluntary ventilation:
MVV, percentage predicted values) in Huntington’s disease (HD) and healthy volunteers (Control)
IC
(% predicted)
MIP (cm H2O)

HD

Control

MEP (cm H2O)

HD

Control

SVC
(% predicted)

FVC
(% predicted)

FEV1
(% predicted)

PEF
(% predicted)

MVV
(% predicted)

r

0.26

0.40

0.75

0.68

0.69

0.56

p

0.293

0.091

0.000

0.001

0.001

0.014

r

0.20

0.14

0.14

0.21

0.16

0.17

p

0.410

0.577

0.558

0.402

0.509

0.479

r

0.18

0.51

0.67

0.64

0.38

0.50

p

0.461

0.028

0.002

0.003

0.113

0.032

r

0.20

0.34

0.27

0.12

0.22

−0.04

p

0.423

0.158

0.262

0.629

0.373

0.848

r values of a Pearson correlation coefficient and p values are shown.

except SVC were negatively correlated with the UHDRSTMS such that the greater the UHDRS-TMS, the
smaller the variables (Figure 1).

Discussion
The results of the present study showed that pulmonary
function was reduced in manifest HD patients when
compared with the age-matched healthy volunteers
(Table 2). Pulmonary function variables were negatively
correlated with UHDRS-TMS, suggesting that decreased
pulmonary function is associated with the severity of
motor abnormalities (Figure 1).
Maximum respiratory pressure values had higher variation in HD patients relative to the control group. Moreover the accuracy of MIP and MEP measurements
improved after the first testing session for both groups.
These results coincide with those reported in reliability
studies of maximal respiratory pressure in patients with
multiple sclerosis [21] and healthy volunteers [14]. The
results suggest that at least one previous testing session
is necessary to achieve more accurate values. It appears
that the learning process takes longer in patients suffering from neurological disorders than it does in healthy
participants.
The subgroup analysis in HD patients and controls revealed no significant differences in pulmonary function
between non-smokers and ex-smokers. As shown previously, spirometry can detect obstructive lung damage
after 20 pack-years of smoking [22]. In the present study
however, both HD and control groups had mean packyears of smoking less than 20, and the time elapsed from
smoke cessation was at least 20 years on average for HD
and control groups. Prospective studies have shown that
decreased lung function in smokers without respiratory
chronic symptoms normalises after 2 years of smoking
cessation [23,24]. Although the subgroup analysis in HD
and controls between non-smokers and ex-smokers

lacks statistical power, the effects of smoking on the pulmonary function were minimal if any in the present
study, and it does not appear that the smoking history
was a confounding factor affecting the variables of the
pulmonary function. In the control group, the 6 exsmokers had lower values (percentage of predicted) of
SVC, FVC, FEV1 and PEF in comparison to those 12
non-smokers, which decreased sprometric indices in the
whole control group (Table 3). Although the 6 exsmokers had values below predicted, these values were
within normal ranges. It should be noted that none of
the participants of the present study had symptoms of
COPD. Thus, the impaired pulmonary function in the
HD patients was due to the disease itself.
The differences presented in this study between
HD patients and control volunteers (e.g. FVC: −21%.
PEF: −16%, MVV: 35%) were similar to those reported in
patients with Parkinson’s disease (PD). Sathyaprabha et al.
[25] reported significantly decreased MIP (−48%),
MEP (−47%) and FVC (−28%) in PD patients compared
with a control group. Polatli et al. [10] reported significantly decreased PEF (−20%) and MVV (−37%) in PD
patients compared to a control group, and also
showed that FVC and MVV (% predicted values) were
correlated (r = −0.65 and r = −0.87, respectively) with disease severity in moderate affected PD patients. Analogous
pathophysiological features of PD and HD may explain
these similar findings between patients with these diseases.
In the present study, MIP exhibited greater positive
correlation with PEF than MEP in the group of HD patients (Table 4). Trebbia et al. [26] reported that MIP
had a higher correlation with peak cough flow than MEP
in patients with neuromuscular disorders. Inspiratory
muscle weakness and reduced inspiratory capacity (IC)
are important factors limiting cough efficacy. The inspired volume of air that precedes coughing determines
the expelled volume of air and the length-tension
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Figure 1 Correlations between Unified Huntington’s Disease Rating Scale-Total Motor Score (UHDRS-TMS) and slow vital capacity (a), forced
vital capacity (b), maximum voluntary ventilation (c), peak expiratory flow (d), maximum inspiratory pressure (e), and maximum expiratory
pressure (f). r values of a Pearson correlation coefficient and p values are included. Spirometric indices are expressed as % of predicted values.

relationship of the expiratory muscles, thus this lengthtension relationship influences the capacity of expiratory
muscles to produce force [27,28]. In the present study,
IC (percentage of predicted value) was significantly reduced in the HD group when compared with the control
group, however IC did not show relevant correlations
with PEF or maximum respiratory pressures. This suggests that in patients with HD, MIP contributes more
than IC to produce a better PEF. Further studies are
needed regarding cough determinants in HD patients.
Motor related manifestations of adult-onset presentation of HD include chorea, bradykinesia, hypokinesia,
akinesia, muscle weakness and rigidity [9,29,30]. Choreic

movements can affect all parts of the body including respiratory and swallowing muscles [29]. The amplitude
and severity of choreic movements vary between individuals. Huntington’s disease patients predominantly show
a choreo-athetoid phenotype, while a smaller proportion
of individuals present an akinetic/rigid state [2]. As the
disease progresses however, choreic movements tend to
decrease and akinesia and rigidity become more prominent [29,31]. It has been reported that bradykinesia is
greater in patients with the akinetic/rigid phenotype
[30,32]. The mechanisms underlying the respiratory
problems in neurodegenerative disorders including HD
are unknown [5], however motor abnormalities such as
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bradykinesia, rigidity and respiratory muscle weakness are
likely to be associated with them. It is important to note
that the pulmonary function parameters related to forced
respiration are mainly affected in manifest HD patients.
The negative correlations between pulmonary function
variables and UHDRS-TMS (Figure 1) suggest that the
greater the movement disorders, the greater the reduction
in the performance of repetitive respiratory tasks such as
MVV, and the smaller the capacity to generate fast and
explosive respiratory muscle contractions required during
FVC, PEF and maximum respiratory pressure manoeuvres.
Although the results of the present study showed decrements of pulmonary function in the HD patient group, it is
important to note that such impairments were not present
in all patients. There were some overlaps in pulmonary
function results between HD patients and healthy participants, suggesting that the nature and severity of pulmonary
complications vary between patients.
Given that pulmonary complications are the major
cause of death in patients with HD and that decreases in
pulmonary function are associated with greater severity
of motor abnormalities, it is important to include pulmonary function tests at early stages of the disease. If
pulmonary function impairment is detected, a specific
intervention such as respiratory muscle training, manually assisted coughing, or mechanical cough assistance
should be implemented to prevent an aspiration pneumonia event. The benefits obtained from these interventions would have a higher impact on HD patients at
early stages of the disease when muscles abnormalities
are not yet severer than those at late stages when muscle
and neural damage become more extensive. How HD
patients respond to respiratory muscle training should
be investigated in future studies.

Conclusion
The results of the present study indicate that pulmonary
function is decreased in individuals with manifest HD.
In addition decreased pulmonary function is associated
with greater severity of motor abnormalities. Pulmonary
function tests are useful to monitor HD patients from early
stages of the disease to prevent future severe respiratory
complications.
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